Providing Integrated Bioanalytical Support
LGC’s Immunogenicity Centre of Excellence has successfully developed a COVID-19 antibody assay suitable for serum and dried blood sampling. Our CE Marked assay can analyze up to 40,000 samples per day using serum or capillary blood collected remotely in the United Kingdom.
The assay for SARS-CoV-2 antibody testing achieves specificity of (95% CI) 100% (97.8-100.0) and sensitivity of (95% CI) 98.0% (87.0-99.0) for samples taken 21 days post positive PCR test.
With over twenty years working to GLP and GCP in one of the world’s most extensive bioanalytical facilities, LGC’s Drug Development Solutions team is dedicated to providing high quality data to help make critical decisions on the safety and efficacy of small and large molecules in drug development.
LGC’s Immunogenicity Centre of Excellence in Cambridge, UK is supported by the latest mass spectrometry and immunochemistry technologies. The team has in-depth expertise in these key areas of bioanalytical science, with successful contributions to biopharmaceutical research.
Immunogloblulins (antibodies) to SARS-Cov-2
LGC is GLP and GCP certified.
LGC's Immunogenicity Centre of Excellence offers their SARS-CoV-2 Antibody tests in the United Kingdom.